|
1. |
Carrier detection for hemophilia B: Evaluation of multiple polymorphic sites |
|
American Journal of Hematology,
Volume 33,
Issue 1,
1990,
Page 1-7
G. Mariani,
A. Chistolini,
H. J. Hassan,
E. Gallo,
Gu Xigen,
M. Papacchini,
T. Di Paolantonio,
A. Fantoni,
Preview
|
PDF (573KB)
|
|
摘要:
AbstractDNA analysis was performed in families with hemophilia B. Restriction fragment length polymorphisms (RFLPs) produced by endonucleases Taql, Xmnl, and Ddel were studied by two factor IX genomic probes, F9(Vlll) and F9(Xlll). Fifty‐seven subjects from ten families were investigated; of them, 31 were carriers (11 obligate and 20 potential). Of the potential carriers, ten displayed laboratory features allowing for a phenotypic diagnosis of heterozygosity. Segregation analysis of the markers was informative in 19/20 potential carriers, which belong to nine of the ten studied families. Among the potential carriers, Taql allowed the carriership assessment in 15 (78.9%), Xmnl in 15 (94.7%), and Ddel in two (10.4%). Diagnosis was not possible in one family since a homozygosity in the key individuals with all the employed enzymes (Taql, Xmnl, Ddel, + BamHI) was found. Hemophilia B syndrome in two families likely results from a new mutation. In one family, a first‐trimester prenatal diagnosis was performed. The use of RFLP analysis allowed us to improve genetic counseling as compared with the phenotypic evaluation by clotting factor assays. Indeed, evaluation of RFLP increased by 26% the carriership assessment of the potential carriers of the hemophilia B tr
ISSN:0361-8609
DOI:10.1002/ajh.2830330102
出版商:Wiley Subscription Services, Inc., A Wiley Company
年代:1990
数据来源: WILEY
|
2. |
Successful treatment of refractory anemia with high‐dose methylprednisolone |
|
American Journal of Hematology,
Volume 33,
Issue 1,
1990,
Page 8-12
Toshiko Motoji,
Masanao Teramura,
Masatomo Takahashi,
Kazuo Oshimi,
Michiko Okada,
Kiyoko Kusakabe,
Hideaki Mizoguchi,
Preview
|
PDF (563KB)
|
|
摘要:
AbstractFive patients with refractory anemia were treated with high‐dose methylprednisolone. An immediate and long‐lasting hematological improvement without serious side effects was achieved in two of the patients, although chromosomal abnormalities persisted in both. The clinical course and laboratory data of these two patients are described. Restoration of normal hematopoiesis was achieved regardless of the enhancement of colony formation of granulocyte progenitor cells by the simultaneous addition of hydrocortisone in vitro. The same treatment was given to six patients who had refractory anemia with an excess of myeloblasts (RAEB), but no improvement was observed in any of these patients. It appears that high‐dose methylprednisolone can be valuable in the treatment of refractory anemia, but is not useful for
ISSN:0361-8609
DOI:10.1002/ajh.2830330103
出版商:Wiley Subscription Services, Inc., A Wiley Company
年代:1990
数据来源: WILEY
|
3. |
Evaluation of reticulocyte counts by flow cytometry in a routine laboratory |
|
American Journal of Hematology,
Volume 33,
Issue 1,
1990,
Page 13-17
David J. Ferguson,
Siow‐Fong Lee,
Philip A. Gordon,
Preview
|
PDF (356KB)
|
|
摘要:
AbstractReticulocyte counting using flow cytometry and a membrane‐permeable fluorescent dye, thiazole orange, was evaluated as an alternative to the conventional manual method. The flow cytometric method was more precise (mean c.v. of 4.3%) than the imprecise manual technique (mean c.v. of 22.4%). Linearity was highly acceptable (r = 0.99) over the reticulocyte count range of 1.8–30.1%.Flow cytometry allows processing of large numbers of samples with reduction in technologist time, and the improved precision and tenfold increase in the number of cells counted should considerably improve the clinical utility of the reticuloctye co
ISSN:0361-8609
DOI:10.1002/ajh.2830330104
出版商:Wiley Subscription Services, Inc., A Wiley Company
年代:1990
数据来源: WILEY
|
4. |
Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: Relation to disease activity and effect of chemotherapy |
|
American Journal of Hematology,
Volume 33,
Issue 1,
1990,
Page 18-26
H. Hasselbalch,
P. Junker,
K. Hørslev‐Petersen,
I. Lisse,
K. D. Bentsen,
Preview
|
PDF (748KB)
|
|
摘要:
AbstractThe serum concentration of the aminoterminal propeptide of type III procollagen (PIIINP) was measured serially in patients with idiopathic myelofibrosis and other myeloproliferative syndromes. Two different assays were applied, the RIA‐gnost assay (Hoechst, Frankfurt, FRG) and a new equilibrium RIA for the N‐terminal propeptide of human type III procollagen (Farmos Diagnostica, Oulu, Finland).A positive correlation was found between the results obtained by the two RIA's (rho = 0.90.P<0.001). The highest propeptide levels were recorded in patients with idiopathic myelofibrosis, particularly in those with active disease. Elevated serum PIIINP levels decreased during treatment with various cytotoxic drugs, including intensive chemotherapy. By contrast, serum PIIINP was unchanged or increased in patients undergoing interferon alpha‐2b therapy.Gel filtration of sera on Sephacryl S‐300 column (Pharmacia, Sweden) showed that smaller PIIINP related peptides dominated in healthy subjects and in osteomyelosclerosis with stable disease. Conversely, the relative proportion of intact propeptide increased in accelerating disease stages and acute myelofibrosis.In conclusion, the present study implicates serum PIIINP as a useful indicator of disease activity in idiopathic myelofibrosis. The propeptide also appears to be a sensitive sero‐marker of chemotherapy effect on fibrogenesis related to clonal myeloproliferation. Finally, the propeptide is suggested as an early predictor of relapse during cytotoxi
ISSN:0361-8609
DOI:10.1002/ajh.2830330105
出版商:Wiley Subscription Services, Inc., A Wiley Company
年代:1990
数据来源: WILEY
|
5. |
Clinical manifestations of essential thrombocythemia in young adults |
|
American Journal of Hematology,
Volume 33,
Issue 1,
1990,
Page 27-31
Frederick E. Millard,
Christine S. Hunter,
Michael Anderson,
Martin J. Edelman,
Michael P. Kosty,
George A. Luiken,
Gregory G. Marino,
Preview
|
PDF (431KB)
|
|
摘要:
AbstractEssential thrombocythemia (ET) is a myeloproliferative disorder characterized by isolated overproduction of platelets, thrombohemorrhagic complications, and a median age of 50–60. When it occurs in younger patients, the incidence of complications has been reported to be quite low, with a good long‐term prognosis. We report a retrospective review of 13 patients with ET between the ages of 22 and 35 in which 11 were symptomatic at diagnosis, with only one remaining asymptomatic during follow‐up. Three patients presented with potentially life‐threatening complications (two myocardial infarctions, one stroke), although no deaths were observed. The majority of the nonlife‐threatening complications were vaso‐occlusive in nature, including erythromelalgia and transient neurologic symptoms. We conclude that ET in young adults is not always a benign disease and that potentially life‐threatening complications are not rare. The optimum approach to treatment in this or any other age group rema
ISSN:0361-8609
DOI:10.1002/ajh.2830330106
出版商:Wiley Subscription Services, Inc., A Wiley Company
年代:1990
数据来源: WILEY
|
6. |
Chromosomal abnormalities define clonal proliferation in CD3‐ large granular lymphocyte leukemia |
|
American Journal of Hematology,
Volume 33,
Issue 1,
1990,
Page 32-38
Masafumi Taniwaki,
Shinichi Tagawa,
Hikari Nishigaki,
Shigeo Horiike,
Shinichi Misawa,
Chihiro Shimazaki,
Taira Maekawa,
Hiroshi Fujii,
Teruo Kitani,
Tatsuo Abe,
Preview
|
PDF (911KB)
|
|
摘要:
AbstractSix patients with lymphoproliferative disorder of large granular lymphocytes (LDGL) were studied for chromosomal abnormalities. When the patients were divided into two groups depending on the expression of a mature antigen of T cell lineage, CD3, two with CD3 + phenotype had a stable disease, whereas three of the four patients with CD3‐ phenotype had marked hepatosplenomegaly and a highly aggressive disease. Chromosomal abnormalities were detected in four of six patients, indicating a clonal proliferation of large granular lymphocytes in individual patients. In particular, chromosomal abnormalities were found in three of the four patients with CD3‐ LDGL. all of which had a germ‐line configuration of the T cell receptor beta‐chain gene. Thus, the chromosomal abnormalities provide definitive evidence for the clonal origin of the expanded cells in the C
ISSN:0361-8609
DOI:10.1002/ajh.2830330107
出版商:Wiley Subscription Services, Inc., A Wiley Company
年代:1990
数据来源: WILEY
|
7. |
Use of DDAVP in inherited and acquired platelet dysfunction |
|
American Journal of Hematology,
Volume 33,
Issue 1,
1990,
Page 39-45
Donna M. Dimichele,
Wm. E. Hathaway,
Preview
|
PDF (648KB)
|
|
摘要:
AbstractTwenty‐one patients with prolonged bleeding times secondary to inherited disorders of platelet function and eight patients with prolonged bleeding times secondary to acquired platelet dysfunction were given 0.3 μg per kilogram of DDAVP, 1‐deamino‐8‐D‐arginine vasopressin, intravenously. Sixteen of twenty‐two DDAVP trials in patients with inherited platelet dysfunction (73%) and seven of the nine DDAVP trials in patients with acquired platelet dysfunction (78%) resulted in normalization or shortening of the prolonged bleeding times by at least 4 min. The bleeding time response did not correlate with changes in the levels of von Willebrand factor (vWf) antigen or ristocetin cofactor activity, nor was it associated with changes in vWf multimeric analysis or in vitro platelet aggregations following the administration of DDAVP. Shortening of the bleeding time with DDAVP was seen in patients with a failure to release/storage pool type defect, thromboxane synthesis type defect, Bernard‐Soulier syndrome, Glanzmann's thrombasthenia, the May‐Hegglin anomaly, liver disease, nonuremic renal disease, myelofibrosis, and T
ISSN:0361-8609
DOI:10.1002/ajh.2830330108
出版商:Wiley Subscription Services, Inc., A Wiley Company
年代:1990
数据来源: WILEY
|
8. |
Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C‐related hemolytic‐uremic syndrome |
|
American Journal of Hematology,
Volume 33,
Issue 1,
1990,
Page 46-49
Juan Monteagudo,
Arturo Pereira,
Susana Roig,
Juan C. Reverter,
Antonio Ordinas,
Ricardo Castillo,
Preview
|
PDF (479KB)
|
|
摘要:
AbstractWe have studied the ability of the plasma to induce aggregation of both homologous and heterologous platelets in four patients with hemolytic‐uremic syndrome (HUS) associated with chemotherapy with mitomycin C (MMC). Neither platelet aggregation was elicited by patients' plasmas nor the in vitro addition of purified von Willebrand factor (vWF) had any effect on the aggregation pattern. In addition, ristocetin‐induced binding of patients' vWF to formaldehyde‐fixed platelets was normal, and multimeric vWF analysis revealed a normal structure of patients' plasmatic vWF whatever the clinical stage in which it was studied. These findings suggest that, in spite of the existence of common clinical and biological features in the various forms of HUS, the pathogenesis of MMC‐related HUS may be, at least in part, different from that of the other forms of HUS in which both platelet‐aggregating activity and alterations in the vWF
ISSN:0361-8609
DOI:10.1002/ajh.2830330109
出版商:Wiley Subscription Services, Inc., A Wiley Company
年代:1990
数据来源: WILEY
|
9. |
Treatment of severe β‐thalassemia (patients) with myleran |
|
American Journal of Hematology,
Volume 33,
Issue 1,
1990,
Page 50-55
Liu De‐pei,
Liang Chih‐chuan,
Ao Zao‐hui,
Jia Pei‐chen,
Chen Song‐sen,
Wang Rong‐xin,
Liu Li‐juan,
Jin He‐qian,
Zha Dan‐yu,
Huang You‐wen,
Preview
|
PDF (445KB)
|
|
摘要:
AbstractWe previously reported that myleran, a cell cycle nonspecific drug, can stimulate γ‐globin gene expression in anemic adult rhesus monkeys. This finding prompted us to treat two patients with severe β‐thalassemia with myleran. Both patients received an initial course of therapy, constantly of myleran at a dosage of 0.2 mg/kg/d for 9 days followed by 0.15 mg/kg/d for the next 11 days. One patient received an additional 20‐day course of myleran at a dosage of 0.2 mg/kg/d beginning 44 days after completion of the first course. No severe ill effects related to the drug were observed during or after drug administration. After 20 days of myleran treatment, levels of HbF and reticulocytes increased in both patients and level of F cells increased in patient 1. In patient 1, Hb concentration rose from 42g/L (9 days after transfusion) before treatment to a maximum of 65g/L afterward; in patient 2, it rose from 74g/L to a maximum of 106g/L. A value of 15g/L above baseline lasted for about 5 months in both patients. Hypomethylation of bone marrow DNA near the γ‐globin gene was demonstrated in
ISSN:0361-8609
DOI:10.1002/ajh.2830330110
出版商:Wiley Subscription Services, Inc., A Wiley Company
年代:1990
数据来源: WILEY
|
10. |
Transient engraftment of syngeneic bone marrow after conditioning with high‐dose cyclophosphamide and thoracoabdominal irradiation in a patient with aplastic anemia |
|
American Journal of Hematology,
Volume 33,
Issue 1,
1990,
Page 56-60
Kosei Matsue,
Takeo Niki,
Shintaro Shiobara,
Mikio Ueda,
Shigeki Ohtake,
Takao Mori,
Tamotsu Matsuda,
Mine Harada,
Preview
|
PDF (801KB)
|
|
摘要:
AbstractWe describe the clinical course of a 16 year old girl with aplastic anemia who was treated by syngeneic bone marrow transplantation. Engraftment was not obtained by simple infusion of bone marrow without immunosuppression. The patient received a high‐dose cyclophosphamide and thoracoabdominal irradiation, followed by second marrow transplantation from the same donor. Incomplete but significant hematologic recovery was observed; however, marrow failure recurred 5 months after transplantation. Since donor and recipient pairs were genotypically identical, graft failure could not be attributed to immunological reactivity of recipient cells to donor non‐HLA antigens. This case report implies that graft failure in some cases of aplastic anemia might be mediated by inhibitory cells resistant to cyclophosphamide and irradiat
ISSN:0361-8609
DOI:10.1002/ajh.2830330111
出版商:Wiley Subscription Services, Inc., A Wiley Company
年代:1990
数据来源: WILEY
|
|